ATR/CHEK1基因突变与胃癌高TMB/MSI-H状态的关系及其对免疫治疗效果的预测作用

雒雯宇 ,  任静怡 ,  艾力菲娅·依力夏提 ,  申情 ,  宋娜

中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (9) : 802 -806.

PDF (499KB)
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (9) : 802 -806. DOI: 10.12007/j.issn.0258‐4646.2026.09.006
论著

ATR/CHEK1基因突变与胃癌高TMB/MSI-H状态的关系及其对免疫治疗效果的预测作用

作者信息 +

Relationship between ATR/CHEK1 gene mutations and high TMB/MSI-H status in gastric cancer and their predictive role on immunotherapy efficacy

Author information +
文章历史 +
PDF (510K)

摘要

目的 探讨胃癌 (GC) 患者共济失调毛细血管扩张突变基因Rad3相关激酶 (ATR) 和检查点激酶1 (CHEK1) 基因突变与肿瘤突变负荷 (TMB)、微卫星状态 (MSS) 及程序性死亡配体1 (PD-L1) 表达的相关性,评估其作为预测免疫治疗效果生物标志物的潜力。方法 回顾性分析594例GC患者的福尔马林固定石蜡包埋组织样本,利用下一代测序技术检测ATR/CHEK1基因突变、TMB和MSS,并通过免疫组织化学检测PD-L1表达。采用Fisher确切概率法、χ2检验、Wilcoxon秩和检验和Spearman相关分析评估变量间的关联性。结果 在594例患者中,检出ATR突变22例 (3.7%),其中3例同时携带CHEK1突变 (0.5%)。ATR突变患者中,高肿瘤突变负荷 (TMB-H) 比例 (63.6%) 和高度微卫星不稳定 (MSI-H) 比例(57.1%) 显著增高。3例ATR/CHEK1双突变患者均为TMB-H和MSI-H,且双突变组的TMB值显著高于ATR单突变组 (P < 0.05)。突变位点分析显示,ATR基因I774Yfs*5移码突变在TMB-H (35.7%) 和MSI-H (41.7%) 患者中高频出现。ATR突变组中有27.3%的患者PD-L1联合阳性评分 (CPS) ≥1。结论 ATR/CHEK1基因突变,特别是双基因突变和I774Yfs*5热点突变,与GC的TMB-H和MSI-H状态相关,其可能通过破坏DNA损伤修复通路增强肿瘤免疫原性。ATR/CHEK1突变状态有望成为预测GC免疫治疗敏感性的新型生物标志物。

Abstract

Objective To explore the correlations between mutations in ataxia telangiectasia and Rad3-related kinase (ATR) and checkpoint kinase 1 (CHEK1) genes and tumor mutational burden (TMB),microsatellite status (MSS),and programmed death-ligand 1 (PD-L1) expression in patients with gastric cancer (GC) and to evaluate their potential as biomarkers for predicting the efficacy of immunotherapy. Methods A total of 594 formalin-fixed paraffin-embedded tissue samples from patients with GC were retrospectively analyzed. Next-generation sequencing (NGS) was used to assess ATR/CHEK1 gene mutations,TMB,and MSS,and immunohistochemistry was performed to analyze PD-L1 expression. Fisher’s exact test,chi-square test,Wilcoxon rank-sum test,and Spearman correlation analysis were used to assess the associations among variables. Results Among the 594 enrolled patients,ATR mutations were identified in 22 patients (3.7%),including three concurrently harboring CHEK1 mutations (0.5%). Patients with ATR mutations had significantly higher proportions of high tumor mutational burden (TMB-H,63.6%) and microsatellite instability-high (MSI-H,57.1%). All three patients with concurrent ATR and CHEK1 double mutations presented TMB-H and MSI-H status,and the TMB level in the double mutation group was markedly higher than that in the ATR single mutation group (P < 0.05). Mutation site analysis revealed that the frameshift mutation I774Yfs*5 of the ATR gene occurred at a high frequency in patients with TMB-H (35.7%) and MSI-H (41.7%). In the ATR mutation group,27.3% of patients had a combined positive score (CPS) of PD-L1≥1. Conclusion This study confirmed that ATR/CHEK1 gene mutations,especially double mutations and the hotspot mutation I774Yfs*5,correlate with TMB-H and MSI-H status in GC,indicating that these mutations may enhance tumor immunogenicity by disrupting the DNA damage repair pathway. Collectively,ATR/CHEK1 mutation status can serve as a novel biomarker for predicting the sensitivity to immunotherapy in GC.

关键词

胃癌 / 共济失调毛细血管扩张突变基因Rad3相关激酶 / 检查点激酶1 / 肿瘤突变负荷 / 微卫星状态 / 程序性死亡配体1

Key words

gastric cancer / ataxia telangiectasia and Rad3-related kinase / checkpoint kinase 1 / tumor mutational burden / microsatellite status / programmed death-ligand 1

引用本文

引用格式 ▾
雒雯宇,任静怡,艾力菲娅·依力夏提,申情,宋娜. ATR/CHEK1基因突变与胃癌高TMB/MSI-H状态的关系及其对免疫治疗效果的预测作用[J]. 中国医科大学学报, 2026, 55(9): 802-806 DOI:10.12007/j.issn.0258‐4646.2026.09.006

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

SUNDAR R,NAKAYAMA I,MARKAR SR,et al. Gastric cancer [J]. Lancet,2025,405 (10494):2087-2102. DOI:10.1016/S0140-6736(25)00052-2.

[2]

BRAY F,LAVERSANNE M,SUNG H,et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin,2024,74 (3):229-263. DOI:10.3322/caac.21834.

[3]

GUAN WL,HE Y,XU RH. Gastric cancer treatment:recent progress and future perspectives [J]. J Hematol Oncol,2023,16 (1):57. DOI:10.1186/s13045-023-01451-3.

[4]

SHITARA K,SHAH MA,LORDICK F,et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma [J]. N Engl J Med, 2024,391 (12):1159-1162. DOI:10.1056/nejmc2409512.

[5]

杨庆林,郭晓东,张睿,等. 胃癌组织中HER-2和Survivin蛋白的表达及临床意义 [J]. 中国医科大学学报,2016,45 (7):616-619. DOI:10.12007/j.issn.0258-4646.2016.07.009.

[6]

LI F,KOZONO D,DERASKA P,et al. CHK1 inhibitor blocks phosphorylation of FAM122A and promotes replication stress [J]. Mol Cell,2020,80 (3):410-422.e6. DOI:10.1016/j.molcel.2020.10.008.

[7]

中国抗癌协会肿瘤精准治疗专业委员会. 二代测序技术在消化系统肿瘤临床应用的中国专家共识 [J]. 肿瘤综合治疗电子杂志, 2024,10 (1):69-92. DOI:10.1215/JMCM.2024.01-11.

[8]

FRAMPTON GM,FICHTENHOLTZ A,OTTO GA,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing [J]. Nat Biotechnol,2013,31 (11):1023-1031. DOI:10.1038/nbt.2696.

[9]

CHALMERS ZR,CONNELLY CF,FABRIZIO D,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J]. Genome Med,2017,9 (1):34. DOI:10.1186/s13073-017-0424-2.

[10]

ZHANG LY,GUAN B,LI W,et al. The effective molecular characteristics of PD-1 inhibitor combination regimen as the first-line treatment for Chinese patients with HER2-positive gastric cancer: a real-world retrospective analysis study [J]. Transl Gastroenterol Hepatol,2025,10:23. DOI:10.21037/tgh-24-95.

[11]

SETHI NS,KIKUCHI O,DURONIO GN,et al. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model [J]. Nat Genet,2020,52 (2):219-230. DOI:10.1038/s41588-019-0574-9.

[12]

XUE KM,LIU L,LIU YX,et al. Radiomics model based on multi-sequence MR images for predicting preoperative immunoscore in rectal cancer [J]. La Radiol Med,2022,127 (7):702-713. DOI:10.1007/s11547-022-01507-3.

[13]

SMITH J,THO LM,XU N,et al. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer [M] //Advances in cancer research. Amsterdam:Elsevier,2010:73-112. DOI:10.1016/b978-0-12-380888-2.00003-0.

[14]

BAO J,YU Y,CHEN JN,et al. miR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/ CHEK1 pathway [J]. Cell Death Dis,2018,9:1045. DOI:10.1038/s41419-018-1020-0.

[15]

WEI ZW,LI J,ZHONG L,et al. DDR1 drives malignant progression of gastric cancer by suppressing HIF-1α ubiquitination and degradation [J]. Adv Sci,2024,11 (35):2308395. DOI:10.1002/advs.202308395.

[16]

JASIM SA,GUPTA J,UTHIRAPATHY S,et al. A comprehensive review of immunotherapy in gastrointestinal tumors with a focus on the role of combination therapy with PARP inhibitors [J]. Naunyn- Schmiedeberg’s Arch Pharmacol,2025,398 (11):15095-15111. DOI:10.1007/s00210-025-04336-z.

基金资助

辽宁省科学技术计划(2021-MS-184)

AI Summary AI Mindmap
PDF (499KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉